(Q53394735)

13 May 2018

title

Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. (English)

1 reference

13 May 2018

1 reference

13

Takuji Tanaka

1 reference

13 May 2018

author name string

Nobuhiko Nakamura

1

1 reference

13 May 2018

Takeshi Hara

2

1 reference

13 May 2018

Masahito Shimizu

3

1 reference

13 May 2018

Ryoko Mabuchi

4

1 reference

13 May 2018

Junji Nagano

5

1 reference

13 May 2018

Tomohiko Ohno

6

1 reference

13 May 2018

Takahiro Kochi

7

1 reference

13 May 2018

Masaya Kubota

8

1 reference

13 May 2018

Yohei Shirakami

9

1 reference

13 May 2018

Naoe Goto

10

1 reference

13 May 2018

Hiroyasu Ito

11

1 reference

13 May 2018

Kuniaki Saito

12

1 reference

13 May 2018

Hisataka Moriwaki

14

1 reference

13 May 2018

Hisashi Tsurumi

15

1 reference

13 May 2018

publication date

5 August 2015

1 reference

13 May 2018

International Journal of Hematology

published in

1 reference

13 May 2018

volume

102

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

327-334

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s12185-015-1835-8

exact match

0 references

cites work

Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Inhibition of T cell proliferation by macrophage tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Peptide vaccines for hematological malignancies: a missed promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

T cell homeostatic proliferation elicits effective antitumor autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

The tumor-draining lymph node as an immune-privileged site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1835-8

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma

1 reference

12 December 2020

Establishment and characterization of BALB/c lymphoma lines with B cell properties

1 reference

12 December 2020

Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers

1 reference

12 December 2020

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

1 reference

12 December 2020

Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells

1 reference

12 December 2020

The Absence of IDO Upregulates Type I IFN Production, Resulting in Suppression of Viral Replication in the Retrovirus-Infected Mouse

1 reference

12 December 2020

Immunotherapy and chemotherapy--a practical partnership

1 reference

12 December 2020

10.1007/S12185-015-1835-8

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018